Primary Biliary Cholangitis Therapeutics Market

Name: Primary Biliary Cholangitis Therapeutics Market - Share & Size
Creator: Mordor Intelligence
License: https://www.mordorintelligence.com/privacy-policy

Primary Biliary Cholangitis Market Size

Primary Biliary Cholangitis Market Trends

Obeticholic Acid to Grow at Significant Rate

Presently, there is no total cure for the disease. But, the liver damage can be delayed using the therapeutics. Ocaliva is a semisynthetic bile acid analogue which is used as a primary drug for the treatment of primary biliary cholangitis.
On the other hand, Ursodeoxycholic acid is a secondary bile acid produced by intestinal bacteria. This shows advanced effects on kidney destruction, but a few percentages of the patient shows intolerance to the drug.
According to the U.S. Department of Health and Human Services, 65 out of 100,000 women and about 10 of 100,000 men in the United States have primary biliary cholangitis.
Moreover, factors such as the increase in R&D investments and presence of robust pipeline in for autoimmune diseases, especially primary biliary cholangitis are anticipated to boost the market growth over the forecast period.

High Performance Liquid Chromatography Trends.png

Understand The Key Trends Shaping This Market

Download PDF

North America to Have Significant Growth

Among the regional segments, North America is projected to have significant market growth owing to well-established healthcare infrastructure, presence of key market players and recent product launches. Moreover, the growing number of patients with the primary biliary cirrhosis and growing demand for the therapeutics is anticipated to fuel the market growth over the forecast period. Ocaliva drug was approved in 2016, in Europe and the United States, and had notable initial sales, however, the recent black box warnings from the regulatory authorities have impacted the usage. There is a tremendous need for the development of new therapeutics, and it is taken up by the market players in the region anticipated to boost the regional growth.

Primary biliary cholangitis (PBC) Therapeutics Market - Growth Rate by Region-Image

Get Analysis on Important Geographic Markets

Download PDF

Primary Biliary Cholangitis Industry Overview

Global primary biliary cholangitis (PBC) therapeutics market is moderately competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Allergan Inc. and Glenmark Pharmaceuticals among others.

Primary Biliary Cholangitis Market Leaders

Intercept Pharmaceuticals, Inc.
Teva Pharmaceutical
Mylan Inc.
Allergan Inc.
Glenmark Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order

Primary Biliary Cholangitis (PBC) Therapeutics Conc.png

Need More Details on Market Players and Competitors?

Download PDF

Primary Biliary Cholangitis Market Report - Table of Contents

1. INTRODUCTION

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Increasing R&D For Development of New Drug Therapeutics For Primary Biliary Cholangitis
- 4.2.2 Growing Burden of Primary Biliary Cholangitis and Liver Related Disorders
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Policies
- 4.3.2 Lack of Awareness Regarding Liver Disorders
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

5.1 By Drug
- 5.1.1 Obeticholic Acid
- 5.1.2 Ursodeoxycholic Acid
- 5.1.3 Others
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle-East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle-East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 Intercept Pharmaceuticals, Inc.
- 6.1.2 Teva Pharmaceutical
- 6.1.3 Mylan Inc.
- 6.1.4 Allergan Inc.
- 6.1.5 Glenmark Pharmaceuticals
- 6.1.6 Eli Lilly and Company
- 6.1.7 Endo International plc
- 6.1.8 Novartis AG
*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Primary Biliary Cholangitis Industry Segmentation

Primary biliary cholangitis also known as primary biliary cirrhosis is an autoimmune disease of the liver. This results from the slow and progressive destruction of the biliary cells. Currently, a limited number of therapeutics are approved for the treatment of primary biliary cholangitis.

By Drug	Obeticholic Acid
	Ursodeoxycholic Acid
	Others

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		Australia
		South Korea
		Rest of Asia-Pacific

	Middle-East and Africa	GCC
		South Africa
		Rest of Middle-East and Africa

	South America	Brazil
		Argentina
		Rest of South America

Need A Different Region or Segment?

Customize Now

Primary Biliary Cholangitis Market Research FAQs

What is the current Primary Biliary Cholangitis (PBC) Therapeutics Market size?

The Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to register a CAGR of 10% during the forecast period (2025-2030)

Who are the key players in Primary Biliary Cholangitis (PBC) Therapeutics Market?

Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Mylan Inc., Allergan Inc. and Glenmark Pharmaceuticals are the major companies operating in the Primary Biliary Cholangitis (PBC) Therapeutics Market.

Which is the fastest growing region in Primary Biliary Cholangitis (PBC) Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Primary Biliary Cholangitis (PBC) Therapeutics Market?

In 2025, the North America accounts for the largest market share in Primary Biliary Cholangitis (PBC) Therapeutics Market.

What years does this Primary Biliary Cholangitis (PBC) Therapeutics Market cover?

The report covers the Primary Biliary Cholangitis (PBC) Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Primary Biliary Cholangitis (PBC) Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Primary Biliary Cholangitis Therapeutics Industry Report

Statistics for the 2025 Primary Biliary Cholangitis (PBC) Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Primary Biliary Cholangitis (PBC) Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.